Consistent with study exclusion criteria, the patient with hepatitis B infection had been negative for hepatitis Bs antigen and antibodies against HBs and HBc at the start of the trial; no risk factors for transmission (i.e., travel to endemic areas, injection drug use, or other exposure) were reported, and the patient discontinued the study because of this event. The gene discussed is KRT88P; the disease is hepatitis B virus infection.